Roche has obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its LightMix Zika rRT-PCR Test.

The test, which is manufactured by TIB MOLBIOL and exclusively distributed by Roche, detects Zika viral RNA in ethylenediaminetetraacetic acid (EDTA) plasma or serum samples using Roche's LightCycler 480 Instrument II, or cobas z 480 Analyzer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test is applicable to patients fulfilling CDC Zika virus clinical and CDC Zika virus epidemiological criteria.

"As a leader in diagnostics, Roche is committed to providing testing solutions for the world's most challenging healthcare emergencies."

Roche Molecular Diagnostics head Uwe Oberlaender said: "The LightMix Zika test is an easy-to-use molecular diagnostic test that enables healthcare professionals to quickly detect the virus.

"As a leader in diagnostics, Roche is committed to providing testing solutions for the world's most challenging healthcare emergencies.

See Also:

“The FDA's granting of this EUA supports our commitment to help healthcare professionals who are working to combat this serious disease."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The fully automated process is performed over a period of 2.5 hours, starting with sample preperation, to issuing the results for up to 96 samples.

The Zika virus is primarily transmitted by Aedes mosquitoes, triggering symptoms such as mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise, or headache.

Infection of a pregnant woman can cause the fetus to develop microcephaly, which is an abnormal smallness of the head, causing incomplete brain development.

Roche is also developing the cobas Zika Test which will be used with the cobas 6800/8800 Systems.